Comparison
Glepaglutide vs. Lanreotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
no data
108736-35-2
Molecular weight
no data
1096.34 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Glepaglutide and Lanreotid?
- Glepaglutide is classified as "Research other", while Lanreotid is classified as "Research other". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Glepaglutide or Lanreotid?
- The highest available evidence level is "Human RCT" for Glepaglutide and "Human RCT" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Glepaglutide and Lanreotid in Germany and the United States?
- Germany: Glepaglutide — Unapproved, Lanreotid — Prescription. United States: Glepaglutide — Unapproved, Lanreotid — Prescription. These are factual summaries with source and review date on the individual pages.